Vaccine risk assessment in children with a referred reaction to a previous vaccine dose: 2009–2011 retrospective report at the Bambino Gesu’ children hospital, Rome, Italy

Italian Journal of Pediatrics

Alberto Villani¹  Annalisa Grandin¹  Alberto Cagigi²  Elena Bozzola¹  Rossella Mancini³  Annachiara Vittucci¹  Luciana Nicolosi¹ 

[1] Pediatric and Infectious Diseases Unit, Pediatric Medicine Department, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy;Immunology and Infectious Diseases Unit; University Hospital Pediatric Department, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy;Faculty of Medicine and Surgery, La Sapienza University, Rome, Italy

关键词: Side effects;    Children;    Vaccination;   

Others  :  1170927
DOI  :  10.1186/1824-7288-40-31

 received in 2013-10-30, accepted in 2014-03-18,  发布年份 2014

【 摘 要 】

Background

During the last century, mass vaccination programs have achieved considerable success across the world in immunizing against several serious infectious diseases. However, vaccinations are threatened by their own success after results have been obtained: the more the incidence of potentially devastating diseases decreases, thanks to the success of vaccination programs, the more public attention shifts towards real or alleged “side effects” of vaccines.

Methods

We analyze the experience of 153 children with “reaction to a previous vaccine dose” continuing the vaccination protocol in the safe environment of the Center for risk vaccination at the Bambino Gesù Children’s Hospital IRCCS in Rome, from 2009 to 2011.

Results

To assess the suitability for vaccination, a specialized pre-vaccination advice and a skin prick test (SPT) was undergone, according to Wood’s guideline; 151 children were SPT negative and full vaccine was administered. Of the 153 children examined just 13 had symptoms suggestive of IgE-mediated reaction-type reactions with angioedema manifestations. Among them, 2 had positive STP, which required alternative measures of administration of the vaccine. No cases of post vaccination reaction was reported and no vaccination program was stopped due to a severe reaction.

Conclusions

Inadequate levels of immunization against infectious diseases remain a significant problem for public health. However, the reasons for incomplete vaccination and non-adoption of vaccination services are manifold. To maintain public confidence in vaccines, advanced immunization programs must include activities for monitoring the safety of the vaccine at the individual level and pursuing specialized counseling pre-and post-vaccination for those at risk. Our results underlined a gap between true and referred adverse reactions and are consistent with vaccine safety. Anyway, a continuous assessment of the risks and benefits of vaccination is required and the results must be disclosed in order to strengthen confidence in the existing and in the new immunization programs.

【 授权许可】

   
2014 Nicolosi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Elena B, Mauro B, Valeria C, Salvatore B, Alberto V: “Infectious diseases and vaccination strategies: How to protect the “unprotectable”? ISRN Prev Med 2013, 2013(765354):5.
• [2]Bozzola E, Bozzola M, Tozzi AE, Nicolosi L, Vittucci A, Villani A: Impact of health care providers’ advice on vaccine refusal for children with an acute nervous system infection. Eur J Pediatr 2014. Correspondence Published online: 2014 Feb 6
• [3]Ropeik D: How society should respond to the risk of vaccine rejection. Hum Vaccin Immunother 2013, 9(8):1815-8.
• [4]Heininger U: The success of immunization-shovelling its own grave? Vaccine 2004, 22:2071-2.
• [5]Guillaume L, Bath PA: A content analysis of mass media sources in relation to the MMR vaccine scare. Health Inform J 2008, 14:323-34.
• [6]American Academy of Pediatrics: Active immunization. In Red Book 2006 Report of the Committee on Infectious Diseases. 27th edition. Edited by Pickering LK, Baker CJ, Long SS, McMillan JA. Elk Grove Village, IL: American Academy of Pediatrics; 2006:446-448.
• [7]Ruggeberg JU, Gold MS, Bayas J-M, Blum MD, Bonhoeffer J, Friedlander S, de Souza BG, Heininger U, Imoukhuede B, Khamesipour A, Erlewyn-Lajeunesse M, Martin S, Mäkelä M, Nell P, Pool V, Simpson N: Brighton collaboration anaphylaxis working group. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2007, 25(31):5675-5684.
• [8]Askenase P: Delayed-type hypersensitivity and cellular immunity. In Allergy principles and practice. 6th edition. Edited by Adkinson NF, Yunginger JY, Busse W, Bochner B, Holgate ST, Simons FE. St Louis, MO: Mosby; 2003:425-452.
• [9]Wood RA, Berger M, Dreskin SC, Setse R, Engler RJ, Dekker CL, Halsey NA: Hypersensitivity working group of the clinical immunization safety assessment (CISA) network. An algorithm for treatment of patients with hypersensitivity reactions after vaccines. Pediatrics 2008, 122(3):e771-7. doi:10.1542/peds.2008-1002
• [10]Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, Motala C, Ortega Martell JA, Platts-Mills TA, Ring J, Thien F, Van Cauwenberge P, Williams HC: Revised nomenclature for allergy for global use: report of the nomenclature review committee of the world allergy organization, October 2003. J Allergy Clin Immunol 2004, 113(5):832.
• [11]Sampson HA, Muñoz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, Brown SG, Camargo CA Jr, Cydulka R, Galli SJ, Gidudu J, Gruchalla RS, Harlor AD Jr, Hepner DL, Lewis LM, Lieberman PL, Metcalfe DD, O'Connor R, Muraro A, Rudman A, Schmitt C, Scherrer D, Simons FE, Thomas S, Wood JP, Decker WW: Second symposium on the definition and management of anaphylaxis: summary report–second national institute of allergy and infectious disease/food allergy and anaphylaxis network symposium. J Allergy Clin Immunol 2006, 117(2):391.
• [12]Mullooly JP, Thompson RS, Bohlke K, Davis RL, Marcy SM, Braun MM, De Stefano F, Black SB, Vaccine Safety Datalink Team: Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics 2003, 112(4):815.
• [13]Advisory Committee on Immunization Practices (ACIP): General recommendations on immunization. National center for immunization and respiratory diseases. MMWR Recomm Rep 2011, 60(2):1.
• [14]Apisarnthanarak A, Uyeki TM, Miller ER, Mundy LM: Serum sickness-like reaction associated with inactivated influenza vaccination among Thai health care personnel: risk factors and outcomes. Clin Infect Dis 2009, 49(1):e18-22.
• [15]Lieberman PL, et al.: Anaphylaxis and anaphylactoid reactions. In Middleton's allergy principles and practice. 6th edition. Edited by Adkinson NFJr, Busse WW, Yunginger JW. St. Louis: Elsevier; 2003:1497.
• [16]Bines J: Intussusception and rotavirus vaccines. Vaccine 2006, 24:3772-6.
• [17]Kelso JM, Greenhawt MJ, Li JT, Nicklas RA, Bernstein DI, Blessing-Moore J, Cox L, Khan D, Lang DM, Oppenheimer J, Portnoy JM, Randolph CR, Schuller DE, Spector SL, Tilles SA, Wallace D: Adverse reactions to vaccines practice parameter 2012 update. J Allergy Clin Immunol 2012, 130(1):25-43.
• [18]Anderson RM: The concept of herd immunity and the design of communitybased immunization programmes. Vaccine 1992, 10:928-35.
• [19]Gallo G, Mel R, Rota MC: Guida alle controindicazioni alle vaccinazioni. Rapporti ISTISAN 09/13.
• [20]La Russa PS, Edwards KM, Dekker CL, Klein NP, Halsey NA, Marchant C, Baxter R, Engler RJ, Kissner J, Slade BA: Understanding the role of human variation in vaccine adverse events: the Clinical Immunization Safety Assessment network. Pediatrics 2011, 127(Suppl 1):S65-73.
• [21]Zanoni G, Berra P, Lucchi I, Ferro A, O'Flanagan D, Levy-Bruhl D, Salmaso S, Tridente G: Vaccine adverse event monitoring systems across the European Union countries: time for unifying efforts. Vaccine 2009, 27:3376-84.